Nitto Denko Corporation (Nitto) has been developing a new
RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with
Prof.Yoshiro Niitsu of Sapporo Medical University. In June 2013, Nitto initiated a phase-1 clinical
study in the US, and it is happy to announce that dosing in healthy volunteers has been completed.
Currently, Nitto is advancing the drug to phase-1/2 clinical study in patients for the assessment of
safety and efficacy.
Nitto’s new anti-fibrotic therapy consists of siRNA which specifically inhibits the cause of fibrosis as
well as a targeted lipid nanoparticle delivery system which can deliver the siRNA to the cells
responsible for fibrosis. Therefore, the new drug has a dual targeting mechanism in both drug delivery
and action. Furthermore, this anti-fibrosis therapy can be a revolutionary drug which leads complete
resolution of liver fibrosis and other organ fibrosis, which is not available so far. Nitto also
obtained relevant granted intellectual properties of therapeutic modality in Japan, US, Europe, China,
Canada, Australia and Korea, as well as drug formulations including siRNA and DDS.
Nitto is also pursuing research activities in tissue regeneration mechanisms related to our therapeutic
modality, in addition to new oncology programs which were derived from fibrosis drug development. Those
research activities are carried out with collaborations and supports from Sapporo Medical University and
Hokkaido University and others.
Nitto plans to initiate phase-1/2 clinical study in US this year in order to assess safety and efficacy
in patients, and expects to collaborate with pharmaceutical company from late phase-2 stage toward
approval from the agency in 2018 or after. Nitto continues to put all efforts to deliver new drugs for
fibrosis and other intractable diseases to patients in need.
* Molecular Targeting DDS: A Drug Delivery System which targets to specific molecule, which enables to
deliver desired amount of drug to only preferable site(s) to be delivered.
* Phase-1 clinical study: Assessment of drug safety in human
* Phase-2 clinical study: Assessment of drug efficacy in human
Nitto produces various products across a broad range of industries through a combination of technologies
based on polymer synthesis, such as industrial tapes and electronics-related materials (e.g. optical
films for LCDs.) In the medical field, Nitto has also been developing businesses related to transdermal
drug delivery patches and nucleic acid synthesis. Nitto will capitalize on its experience in these areas
to develop therapeutic agents in the future. Nitto will continue to create new value and businesses in
the “Green (environmental), Clean (new energy) and Fine (life sciences)” business
domains.
请注意
此处登载的信息是当天公布的信息。可能与您在其他媒体上看到的信息有不同之处,请知晓。